{
    "2019-08-16": [
        [
            {
                "time": "2018-03-15",
                "original_text": "How AbbVie Plans To Take On Pfizer, Lilly â€” And Kick Its Humira Habit",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Pfizer",
                        "Lilly",
                        "Humira"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Pipeline",
                        "Regulatory",
                        "JNJ",
                        "LLY",
                        "AZN",
                        "RHHBY"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Filgotinib",
                        "MAA",
                        "RA",
                        "Europe"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}